文献速递关节外科

基于全血细胞计数比值识别可能从围手术期地塞米松获益的全关节置换患者

Complete Blood Cell Count-Based Ratios Identify Total Joint Arthroplasty Patients Likely to Benefit from Perioperative Dexamethasone.
PubMed 文献 · J Bone Joint Surg Am · 2024-11-20

本研究基于Premier医疗数据库,纳入2016至2021年32,849例择期初次全髋或全膝关节置换患者,采用多变量逻辑回归分析围手术期地塞米松暴露与全血细胞计数比值(包括中性粒细胞-淋巴细胞比值和单核细胞-淋巴细胞比值)对90天术后并发症及住院时间≥3天的交互作用,发现较高的术前比值与地塞米松更大边际获益相关。

要点

  • 中性粒细胞-淋巴细胞比值>1.00时,地塞米松组术后并发症概率更低(所有p<0.05)。
  • 中性粒细胞-淋巴细胞比值最高四分位(≥4.67)者,地塞米松与住院时间≥3天几率降低相关(p=0.002)。
  • 单核细胞-淋巴细胞比值≥0.36时,地塞米松组术后并发症几率显著更低。

核心结论

  • 较高的中性粒细胞-淋巴细胞比值和单核细胞-淋巴细胞比值与围手术期地塞米松治疗更大的边际获益相关,在全关节置换中建立了不良结局与围手术期炎症之间的可改变联系。

研究设计与样本

  • 回顾性队列研究,查询Premier医疗数据库,纳入2016年至2021年期间接受择期初次全髋或全膝关节置换的成年患者,共32,849例(全髋12,788例[38.93%],全膝20,061例[61.07%]),其中22,282例(67.83%)接受围手术期地塞米松;采用多变量逻辑回归模型,以地塞米松暴露和全血细胞计数比值为自变量,评估90天术后并发症和住院时间≥3天。

主要发现

  • 在中性粒细胞-淋巴细胞比值>1.00的患者中,接受地塞米松者术后并发症概率更低(所有p<0.05)。
  • 中性粒细胞-淋巴细胞比值最高四分位(≥4.67)患者中,地塞米松与住院时间≥3天几率降低相关, compared with 最低四分位(<1.84)(p=0.002)。
  • 单核细胞-淋巴细胞比值≥0.36的患者中,接受地塞米松者术后并发症几率显著更低。
  • 单核细胞-淋巴细胞比值≥0.33(最高两个四分位)患者中,地塞米松与住院时间≥3天几率降低相关, compared with <0.24(最低四分位)(p=0.039)。

局限性

  • 证据等级为预后III级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complete blood cell count-based ratios (CBRs), including the neutrophil-lymphocyte ratio (NLR) and monocyte-lymphocyte ratio (MLR), are inflammatory markers associated with postoperative morbidity. Given the link between the surgical stress response and complications after total joint arthroplasty (TJA), this study aimed to evaluate whether higher preoperative CBR values predict greater postoperative benefits associated with dexamethasone utilization. METHODS: The Premier Healthcare Database was queried for adult patients who underwent primary, elective total hip or knee arthroplasty (THA or TKA). Multivariable logistic regression models using dexamethasone exposure and CBRs as independent variables assessed primary end points of 90-day postoperative complications and length of stay (LOS) of ≥3 days. The probability difference between the dexamethasone and non-dexamethasone groups for each primary end point was determined across all values of each CBR. Probability differences were compared across CBR quartiles. RESULTS: A total of 32,849 primary, elective TJAs (12,788 THAs [38.93%], 20,061 TKAs [61.07%]) performed between 2016 and 2021 were identified, and 22,282 (67.83%) of the patients received perioperative dexamethasone. Among patients with an NLR value of >1.00, those receiving dexamethasone had a lower probability of postoperative complications (all p < 0.05). Dexamethasone was associated with lower odds of an LOS of ≥3 days among patients in the highest NLR quartile (≥4.67) compared with the lowest quartile (NLR <1.84) (p = 0.002). Among patients with an MLR value of ≥0.36, those receiving dexamethasone had significantly lower odds of postoperative complications. Dexamethasone was associated with lower odds of an LOS of ≥3 days among patients with an MLR of ≥0.33 (the 2 highest quartiles) compared with an MLR of <0.24 (the lowest quartile) (p = 0.039). CONCLUSIONS: Higher NLR and MLR values were associated with greater marginal benefit from perioperative dexamethasone treatment, establishing a modifiable link between adverse outcomes and perioperative inflammation in TJA. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Wier J, Jones IA, Palmer R, et al. Complete Blood Cell Count-Based Ratios Identify Total Joint Arthroplasty Patients Likely to Benefit from Perioperative Dexamethasone. J Bone Joint Surg Am. 2024. PMID: 39812724. doi:10.2106/JBJS.24.00184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。